These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
50. Risk Stratification Using Cerebrospinal Fluid Biomarkers in Patients with Mild Cognitive Impairment: An Exploratory Analysis. Michaud TL; Kane RL; McCarten JR; Gaugler JE; Nyman JA; Kuntz KM; J Alzheimers Dis; 2015; 47(3):729-40. PubMed ID: 26401707 [TBL] [Abstract][Full Text] [Related]
51. Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition. Reijs BLR; Ramakers IHGB; Elias-Sonnenschein L; Teunissen CE; Koel-Simmelink M; Tsolaki M; Wahlund LO; Waldemar G; Hausner L; Johannsen P; Vanderstichele H; Verhey F; Devanand DP; Visser PJ J Alzheimers Dis; 2017; 60(3):1025-1034. PubMed ID: 28984603 [TBL] [Abstract][Full Text] [Related]
52. Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. Bondi MW; Edmonds EC; Jak AJ; Clark LR; Delano-Wood L; McDonald CR; Nation DA; Libon DJ; Au R; Galasko D; Salmon DP J Alzheimers Dis; 2014; 42(1):275-89. PubMed ID: 24844687 [TBL] [Abstract][Full Text] [Related]
53. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting. Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117 [TBL] [Abstract][Full Text] [Related]